RIS Rx

Overview

RIS Rx is a manufacturer-facing healthcare technology company focused on one narrow but increasingly painful problem: gross-to-net leakage inside affordability, bridge, PAP, and reimbursement workflows. Founded in 2020 by pharmacists Gerard Rivera and Stephen Hom, RIS Rx is a real-time GTN revenue-protection overlay that sits alongside existing copay vendors, hubs, and pharmacy flows rather than replacing them. Summit Partners led a 2025 growth investment, signaling an institutional capital partner behind the platform.

RIS Rx is not a hub services platform, a finance system of record like IntegriChain or Model N, or a stand-alone copay card administrator. It is an operating overlay embedded inside live patient-support transactions, with the commercial model explicitly tied to dollars protected rather than a fixed services fee.

Affordability Capability Model

The framework below standardizes how Rx Almanac evaluates copay-financial-assistance capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, RIS Rx is evaluated as manufacturer-facing healthcare technology company focused on one narrow but increasingly painful problem: gross-to-net leakage inside affordability, bridge, PAP, and reimbursement workflows.

Capability	Buyer should compare	RIS Rx readout
Copay card design and claims adjudication	Program setup, BIN/PCN/group logic, real-time pharmacy adjudication, benefit limits, reversals, and claims reconciliation.	Overlay role. RIS Rx monitors copay adjudication transactions in real time rather than running the copay program itself; pair with the manufacturer’s existing copay administrator.
PAP, foundation, and free-drug support	Eligibility screening, income verification, foundation routing, free-drug workflows, renewals, and bridge program administration.	Core affordability operations. Real-time rules engine covers copay, PAP, bridge, and reimbursement workflows for leakage detection and revenue protection.
Accumulator, maximizer, and affordability controls	Detection and mitigation of accumulator/maximizer exposure, plan edits, alternative funding, and program rule tuning.	Core affordability operations. Accumulator and maximizer exposure detection sits at the center of the GTN revenue-protection lane.
Eligibility, enrollment, and patient communications	Digital enrollment, status updates, patient support, card activation, reminders, and multilingual service workflows.	Intake workflow. Eligibility and government-program screening included; ask how patient communications are routed back through the hub or copay vendor.
Payment rails, debit/card, and pharmacy integration	Card issuing, debit rails, reimbursement, pharmacy switch connectivity, payment settlement, and vendor integrations.	Confirm payment rails in the RFP. RIS Rx integrates with the manufacturer’s existing pharmacy and adjudication rails; confirm which integrations are live versus build-required.
Compliance, reporting, and GTN visibility	Program controls, audit trails, utilization reports, budget visibility, GTN impact, and manufacturer dashboards.	Core reporting layer. GTN visibility is the headline use case; ask for sample dashboards, audit-trail outputs, and reporting cadence at brand and payer level.

Buyer Fit

• Evaluation trigger: Manufacturers experiencing gross-to-net leakage in copay, PAP, bridge, or reimbursement workflows who want a focused overlay alongside their existing hub and copay administrator.
• Best-fit buyers: Mid-size and large pharma manufacturers with 1+ brand in market, established hub or copay vendor relationships, and meaningful exposure to accumulator, maximizer, or alternative-funding leakage.
• Less ideal fit: Pre-launch brands looking for a primary hub or copay administrator; RIS Rx is an overlay, not a replacement.
• Commercial fit: Revenue-share / savings-share pricing tied to dollars protected, with optional module selection rather than a bundled scope; confirm savings-attribution methodology and audit rights.
• Decision checks: Pharmacy and copay-vendor integrations, accumulator/maximizer detection logic, PAP renewal workflows, data ownership, anti-kickback and state-law review responsibilities, and how RIS Rx coordinates with the manufacturer’s existing hub and finance teams.

Differentiators

• Bolt-on deployment alongside existing hubs and copay vendors: RIS Rx is built as an overlay, removing the need to displace incumbent copay, hub, or pharmacy vendors to capture GTN savings.
• Real-time rules engine across copay, PAP, bridge, and eBV workflows: Detection and rule-tuning sit inside live transactions rather than retrospective batch reconciliation.
• Operating scale: Public materials cite 3M+ patients and 35K+ daily transactions monitored, indicating production-scale deployment rather than pilot-only footprint.
• Manufacturer book of 150+ brands and 20+ manufacturers: Diligence-grade reference base across multiple manufacturers.
• Savings-oriented commercial model: Pricing is tied to dollars protected rather than a fixed services fee, with optional module selection; verify savings attribution and reporting methodology in the SOW.

RFP Questions

• How does RIS Rx detect accumulator, maximizer, and alternative-funding exposure inside live adjudication transactions before it erodes conversion?
• Which copay, hub, pharmacy switch, and eBV integrations are already live versus build-required for the manufacturer’s specific stack?
• What PAP, bridge, and reimbursement workflows are covered, and how do detection rules adapt by brand and payer?
• How is GTN savings attributed and audited, and what reporting can be delivered at brand and payer level?
• What anti-kickback, state-law, and PBM compliance controls govern the overlay model?
• How does RIS Rx coordinate operationally with the manufacturer’s existing hub, copay, finance, and trade teams?
• Which references can demonstrate measurable GTN savings or leakage reduction in a comparable therapy area?

Recent Activity

• 2026-03: Public rebrand and positioning sweep around GTN revenue-protection as a category; updated platform messaging and case-study set.
• 2025-06: Summit Partners led a growth investment, signaling institutional capital backing for platform scaling.
• 2024-2025: Continued expansion of manufacturer book to 150+ brands and 20+ manufacturers across multiple therapy areas.